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The relationship between cancer incidence and residence near radiologically 
contaminated hazardous waste sites in New Jersey was examined. Thirteen years of cancer 
incidence data (1979-1991) were collected for six towns contaminated from three Superfund 
sites: the U.S. Radium site in Orange; the Montclair/West Orange Radium Site located in 
Montclair, West Orange, and Glen Ridge; and the Welsbach and General Gas Mantle 
Contamination Sites located in Camden City and Gloucester City. Numerous properties within 
the six towns were contaminated by radium or thorium waste products dating back to the early 
twentieth century. The objective of the study was to evaluate whether the population residing 
closest ttr the contaminated areas had elevated cancer incidence.
The study area consisted of census blocks within approximately two city blocks of areas 
with documented contamination. The census blocks were grouped together into a total focus 
area for each Superfund site. Each total focus area was evaluated separately and combined 
with the other sites to form the total study area. In addition, a more restrictive study area 
designation (called the prime area) was developed to include the population residing within 
about one city block of the contaminated areas. Cancer data from the New Jersey State Cancer 
Registry, a population-based cancer incidence registry, was utilized for the study.
Standardized incidence ratios (SIRs) were calculated for all cancers combined and 
eleven site-specific cancers. Males and females were evaluated separately, and all races were 
combined in the analyses. Expected numbers were calculated using average state incidence 
rates and U.S. census data to estimate the population.
When compared to average state rates, the number of newly diagnosed cancers in the 
total study population was not higher than expected for all cancer combined or any of the 
eleven type-specific cancer groupings. The U.S. Radium focus area had significantly lower 
total cancer incidence (SIR=0.78; 95% confidence interval (Cl) =0.66, 0.91) while the 
Welsbach/General Gas Mantle focus areas had significantly higher total cancer incidence 
(SIR =1.11; 95% CI = 1.01, 1.22) and total cancer in males (SIR= 1.18; 95% CI = 1.03-
1.36). The higher total cancer incidence for the Welsbach sites appears to be due to 
significantly higher lung cancer incidence in this population (all race-sex groups, SIR=1.39; 
95% CI=1.11, 1.73; males only, SIR=1.59; 95% CI=1.20, 2.06). While total cancer 
incidence was unremarkable for the Montclair/West Orange Radium sites, total pancreatic 
cancer (SIR =1.77; 95% C l=1.03, 2.83) and thyroid cancer in females (SIR=2.72; 95%
Cl = 1.09, 5.61) were significantly higher than expected.
When the study area was reduced to the prime areas, only one SIR remained 
significant. SIRs for the prime areas were similar to the total focus areas but were based on 
smaller observed and expected numbers. Lung cancer incidence for the total population near 
the Welsbach/General Gas Mantle sites remained significantly higher than expected 
(SIR= 1.45; 95 % C l=1.05, 1.95). Only two cases of thyroid cancer were diagnosed among 
persons residing in the total prime area, neither of which resided near the Montclair/West 
Orange sites.
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Interpretation of these data should be done cautiously. Numerous limitations exist 
within the study design, including the inability to assess past individual exposure levels in the 
community leading to exposure misclassification, lack of knowledge of length of residence for 
case subjects, the potential impact of population migration, and the absence of information on 
other risk factors, such as occupational exposures or personal life-style habits.
In conclusion, this study found little consistency in the results across focus areas. 
Although lung cancer incidence was significantly elevated near the Welsbach/General Gas 
Mantle sites, and total pancreatic cancer and thyroid cancer in females were significantly 
elevated near the Montclair/West Orange sites, information on important confounding factors 
that might explain the elevations was not available for the analysis.
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INTRODUCTION
During the late nineteenth and early twentieth centuries, a number of industrial 
facilities in New Jersey processed radiological ores and utilized the purified extracts for 
commercial products. Consequent to those operations, several of the manufacturing properties 
and surrounding off-site areas were significantly contaminated with radiological wastes. The 
U.S. Environmental Protection Agency (EPA) has placed three of the sites on the National 
Priority List, a listing of the most contaminated sites in the nation. The first site is U.S. 
Radium (formerly called Radium Luminous Materials Corporation; CERCLIS No. 
NJD9890654172) in Orange and West Orange, Essex County. The second site is known as the 
Montclair/West Orange Radium site (CERCLIS No. NJD980785653) and is comprised of 
several contaminated areas in Montclair, West Orange, and Glen Ridge, Essex County. The 
third site is known as the Welsbach and General Gas Mantle Contamination sites (CERCLIS 
No. NJD986620995) and is located in several sections of Camden City and Gloucester City, 
Camden County.
The U.S. Radium facility, which operated between 1915 and 1926, extracted and 
purified radium-226 from camotite ore (K2(U02)2(V04)23H20 ). The plant processed 
approximately two tons of ore daily, creating large quantities of process wastes and tailings 
containing radioisotopes. These wastes (approximately 1,600 tons) were stored on-site and 
subsequently transported to rural areas in Essex County and dumped with refuse as landfill.
The facility manufactured watch and instrument dials, gun sights, and survey equipment that 
were coated with a luminescent paint produced from the processed ore (ATSDR, 1989 and 
1997a). A wide area around the facility (as well as numerous satellite properties distant from 
the facility) was eventually contaminated with radioactive waste.
The Montclair/West Orange Radium Site is comprised of three distinct areas of 
radiological contamination. The first area consists of approximately 100 acres in Montclair 
and West Orange. The second area, located in West Orange, covers about 20 acres. The third 
area, located in Glen Ridge, consists of approximately 90 contaminated acres. The industrial 
activities at the U.S. Radium plant have been attributed as the source of contamination for 
these areas. Residential development occurred after contaminated fill from U.S. Radium was 
deposited in these areas (ATSDR 1995).
The Welsbach and General Gas Mantle Contamination sites were detected during an 
aerial gamma radiation survey contracted by the U.S. Environmental Protection Agency in 
May 1981. Elevated gamma levels were discovered at two former gas mantle factories and 
several residential areas in Camden County. At the time of the aerial survey, the factories had 
been closed for about 40 years. The residential properties appear to have been contaminated 
by off-site dumping of waste materials from the plants prior to residential development 
(ATSDR, 1997b).
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Little information is available concerning the activities at the former General Gas 
Mantle Company, other than its production of incandescent gas mantles from approximately 
1915 until 1941. It also used and resold radium, thorium, and mesothorium during that time 
period.
The Welsbach Company operated from 1896 to 1940 and also manufactured 
incandescent gas mantles, and at one point was the largest producer of gas mantles in the 
world. At its peak it produced about 250,000 mantles per day. The Welsbach manufacturing 
process used a highly purified solution of 99 % thorium nitrate and 1 % cerium nitrate as the 
lighting fluid. Monazite sands (which contain approximately 5 % thorium as Th02) were the 
primary source of thorium and cerium. At the time, the extraction process and purification of 
thorium generated large quantities of byproducts with little or no commercial value. During 
the years that Welsbach and General Gas Mantle operated, ore tailings were used as landfill in 
the vicinity of the factories, which were located in relatively undeveloped marshlands along the 
Delaware River.
Environmental monitoring for gamma radiation, radon, and progeny indicate that 
monazite tailings and other byproducts were disposed as landfill at many properties in Camden 
City and Gloucester City. Some of these properties were later developed for residential 
housing (ATSDR, 1997b). The radiological contamination has existed for more than 50 years 
in these areas.
Public Health Assessments or Consultations have been prepared for each of the three 
Superfund sites. For all three sites, there is evidence that chronic exposure to radiological 
waste had occurred in the past which constituted a public health threat to residents of those 
areas. On the basis of this information, the Agency for Toxic Substances and Disease Registry 
(ATSDR) and the New Jersey Department of Health and Senior Services (NJDHSS) jointly 
agreed that a cancer statistics review for each of the sites needed to be conducted. The 
purpose of this investigation was to evaluate cancer incidence in populations living in relatively 
close proximity to areas contaminated with radiological industrial wastes.
METHODS
Study Area and Population
The study area for the Radiological Cancer Study was developed to include a large 
enough population to provide meaningful statistics and restrictive enough to include only those 
persons living relatively close to three Superfund sites with documented radiological 
contamination. The three Superfund sites include U.S. Radium site in Orange, the 
Montclair/Glen Ridge/West Orange contaminated areas, and the Welsbach and General Gas 
Mantle sites in Camden City and Gloucester City.
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Census blocks with contaminated properties or census blocks located within 
approximately two city blocks of the areas with documented contamination were grouped 
together and designated as the total focus area for each site. Census blocks are geographic 
areas defined by the Bureau of the Census, U.S. Department of Commerce for the purpose of 
compiling demographic information. Each total focus area was evaluated separately and 
combined with one another to form the total study area. In addition, a more restrictive study 
area designation (called the prime area) was developed to include the population residing 
within about one city block of the contaminated areas (see Figures 1 and 2).
The study population consisted of all residents living in the specified census blocks. 
For the purpose of calculating statistics for this investigation, the 1990 federal population 
estimates (Bureau of the Census, U.S. Department of Commerce, 1990) were utilized for the 
census blocks. The total population for all five towns included in the study decreased by less 
than 0.5 % between the 1980 to the 1990 Census surveys. Because the 1980 census block 
statistics were not available, the 1990 population figures provide the most representative 
estimate of the size and age structure of the studied population.
Case Subject Ascertainment and Study Period
The New Jersey State Cancer Registry was used for the ascertainment of cancer cases. 
The Cancer Registry, operated by the New Jersey Department of Health and Senior Services 
(NJDHSS), is a population-based cancer-incidence registry covering the entire state of New 
Jersey. By law, all cases of newly diagnosed cancers are reportable to the Registry (N.J.S.A. 
26:2-104 et. seq.). In addition, the Registry has reporting agreements with the states of New 
York, Pennsylvania, Delaware and Florida. Information on New Jersey residents that are 
diagnosed in those states is supplied to the New Jersey State Cancer Registry. The Registry 
has been in operation since October 1, 1978.
The study period for this investigation was January 1, 1979, through December 31, 
1991, thirteen full years of observation. A "case subject" was defined as an individual who 
was diagnosed with a new primary malignant cancer during the study period while residing in 
one of the selected census blocks.
The information for each newly diagnosed case available from the Cancer Registry is 
limited. The basic source for the Registry was documented information from the patient's 
medical record. The collected information includes demographic and medical data on each 
cancer patient. Variables used to analyze the level of cancer in the study area include: name, 
address at time of diagnosis, state municipality code, census tract code, primary cancer site, 
histology type, date of diagnosis, age at diagnosis, date of birth, race, sex, and NJDHSS 
Registry identification number. Each cancer is topographically and morphologically coded
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using the second edition of the International Classification o f Disease for Oncology (WHO, 
1990).
Information on other risk factors such as occupational exposures or personal lifestyle 
habits are not available in the abstracted medical information used in this study. The potential 
risk factors that cannot be accounted for in the study design may vary within the study area or 
relative to the State as a whole.
To ensure that all possible cases for the study area were located, Registry data were 
requested for all cases identified as living in Orange, West Orange, Montclair, Glen Ridge, 
Gloucester City and Camden City. All case residential addresses were evaluated for study - 
area inclusion.
Data Analysis
Analyses were completed for all malignant cancer types combined and for select cancer 
types for the entire study area (i.e., all specified census blocks combined) and each Superfund 
site separately. The select cancer types analyzed include: bladder, brain and central nervous 
system, pancreas, lung and pleura, leukemia, non-Hodgkin's lymphoma, liver, bone, kidney, 
and female breast. The cancer types were jointly decided on through discussion by research 
staff at ATSDR and NJDHSS. Through the peer review process, it was suggested that thyroid 
cancer and cancer of the spleen be analyzed in addition to the other types. Thyroid cancer has 
been added to the analysis, however, cancer of the spleen was investigated but not analyzed 
because there were no cases in the study population. These cancer types were selected because 
they represent groupings that may be more sensitive to the effects of radiation exposure.
Males and females were evaluated separately. All races were combined for the analyses.
Standardized incidence ratios (SIRs) were used for the quantitative analysis of cancer 
incidence in the study areas (Kelsey, Thompson and Evans, 1986; Breslow and Day, 1987). 
The SIR is calculated by dividing the observed number of cases (from the Registry) by an 
expected number of cases for the surveyed population during the time period reviewed.
SIR = observed cases -j- expected cases
The expected number was derived by multiplying a comparison population's age-sex- 
specific incidence rates and the study area age-sex-specific population figures. The 
comparison rates used to derive the expected number of cases were the New Jersey average 
annual incidence rates (1986-1988). This time period provides a sufficient number of cases 
statewide for stable age-sex-specific rates and is representative of statewide cancer incidence 
during the study period. The study area age-sex-specific population was determined from
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Bureau of the Census, U.S. Department of Commerce, 1990 data. The 1990 population data 
was used because each municipality’s population remained relatively stable through the 1980's 
and census block information was more readily available for the 1990 census. The age- 
specific population groups were 0-4, 5-17, 18-44, 45-64, and 65 or older. The formula for 
deriving the expected number of cases is shown below (where i represents each age-specific 
category).
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Yj (age-specific rate^ x (age-group population^ 
i = l
Evaluation of the observed and expected numbers is accomplished by interpreting the 
ratio of these numbers. If the observed number of cases equals the expected number of cases, 
the SIR will equal one (1.0). When the SIR is less than one, we conclude that fewer cases 
were observed than expected. Should the SIR be greater than one, then more cases than 
expected were observed.
Random fluctuations may account for some SIR deviations from 1.0. Statistical 
significance of deviations from SIR equal to 1.0 was evaluated using a 95% confidence 
interval (Cl) (Breslow and Day, 1987). The 95% Cl was used to evaluate the probability that 
the SIR may be greater or less than 1.0 due to chance alone and was based on the Poisson 
distribution. Approximations of the upper and lower limits were calculated as follows 
(Breslow and Day, 1987; Checkoway, Pearce, and Crawford-Brown, 1989).
Lower limit of the SIR:
Observed x [ l  - ( 1 t ( 9  x Observed)) - ( z a / 2 (3 x Observed °*5) ) ]  3-^Expected
Upper limit of the SIR:
(Observed+1) x ( l  -r (9 x (Observed +1))) + (Za/2 (3 x (Observed* l ) 0'5) ) ] 3 -r- Expected
If the confidence interval is 1.0, then the SIR is not considered to be significantly different 
than 1.0.
RESULTS
Tables la through Id display the number of malignant incident cases by race, age- 
group, year of diagnosis, and sex for the total study area and the three focus areas. A total of
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940 cancers were diagnosed in residents living in the total study area, with nearly equal 
division between the sexes. A majority of the cases (80.4%) were identified as white. Only 
six of the cases were in children under the age of 20. Cases appeared to be relatively evenly 
distributed throughout the study period.
Of the total study area cases, approximately 45 % lived in the Welsbach/General Gas 
Mantle focus area, 39% in the Montclair/West Orange focus area, and 16% in the U.S. 
Radium focus area. Although the sex ratio was similar for each of the areas, the race of the 
cases differed sharply among focus areas: Welsbach/General Gas Mantle was nearly 93% 
white, Montclair/West Orange was nearly 79% white, and U.S. Radium was just over 50% 
white. Three of the six childhood cases resided in the U.S. Radium focus area.
Tables 2a through 2d present a description of the cases by cancer type and sex for the 
total study area and the focus areas separately. For males, the most frequent cancer type was 
lung and pleura (107) followed by prostate (83) and colorectal (65). For females, the most 
frequent cancer type was breast (142), followed by colorectal (81) and lung and pleura (43). 
The three most common cancer types were generally congruous across focal areas and 
consistent with New Jersey State cancer incidence data.
Tables 3a through 3d present standardized incidence ratio (SIR) results for the total 
study area and focus areas by total population and sex. Of the 34 SIRs calculated for the total 
study area (Table 3a), two were significantly lower than expected, bladder cancer in females 
(SIR=0.38; 95%CI=0.12, 0.89) and leukemia in females (SIR=0.38; 95% CI=0.10, 0.98), 
while none were significantly higher than expected.
For the U.S. Radium focus area (Table 3b), none of the SIRs were significantly 
elevated, while five were significantly lower than expected: all cancers combined for males 
(SIR=0.74; 95%CI=0.58, 0.94), females (SIR=0.80; 95%CI=0.63, 0.99) and total 
population (SIR=0.78; 95%CI=0.66, 0.91), lung and pleural cancer in females (SIR=0.27; 
95%CI=0.05, 0.79), and non-Hodgkin’s lymphoma in the total population (SIR=0.15;
95%CI=0.00, 0.81).
Pancreatic cancer in the total population (Table 3c) was significantly elevated for the 
Montclair/West Orange focus area (SIR =1.77; 95 % C l=1.03, 2.83). Although pancreatic 
cancer was not significantly elevated for either of the sexes, the magnitude of the sex-specific 
SIRs was similar to the SIR for the total population. Total thyroid cancer (SIR=2.31; 
95%CI=1.01, 4.56) and thyroid cancer in females (SIR=2.72; 95%CI = 1.09, 5.61) were also 
significantly elevated. The rate of thyroid cancer in the total population appears to be driven 
by the incidence in the female population. None of the SIRs was significantly lower than 
expected for the Montclair/West Orange focus area.
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Four of the SIRs were significantly elevated for the Welsbach/General Gas Mantle 
focus area (Table 3d): all cancers combined for both the total population (SIR= 1.11; 
95%CI=1.01, 1.22) and males (SIR=1.18; 95%CI=1.03, 1.36) and lung and pleural cancer 
for both the total population (SIR =1.39; 95%CI = 1.11, 1.73) and males (SIR=1.59;
95 % C l=1.20, 2.06). In both instances, the elevations found for the total population appear to 
be driven by the excess male incidence.
Table 4 presents the frequency distribution for children (under age 20) by sex and 
cancer type. A total of six cases of cancer were diagnosed in children living in the total study 
area. The expected number for this population was 4.2 cases over the 13 year study period. 
The observed and expected number of childhood cancer cases were not significantly different.
Tables 5 through 7 present the cancer incidence for the prime areas (within one city 
block of the contaminated sites). Approximately 37 percent (347 of 940 cases) of the total 
study area cancer incidence occurred in residents living closest to the contamination. 
Lung/pleura cancer incidence was significantly elevated for the total population in the 
Welsbach/General Gas Mantle prime area (SIR =1.45; 95% Cl = 1.05, 1.95), while none of 
the SIRs were significantly low.
DISCUSSION
The purpose of this investigation was to evaluate cancer incidence in populations living 
in relatively close proximity to areas contaminated with radiological industrial wastes. Based 
on average State rates, the number of newly diagnosed cancers in the total study population 
was not higher than expected for all cancers combined or any of the eleven type-specific 
groupings. While total cancer incidence was unremarkable for the Montclair/West Orange 
sites, total pancreatic cancer and thyroid cancer in females were significantly higher than 
expected. The U.S. Radium focus area had significantly lower total cancer incidence, while 
the Welsbach/General Gas Mantle areas had significantly higher total cancer incidence. The 
higher total cancer incidence for the Welsbach/General Gas Mantle areas appears to be due to 
the significantly higher lung cancer incidence in this population, especially in males.
When the study area was reduced to the prime areas, only one SIR remained 
significant. The magnitude of the SIRs for the prime areas were similar to those of the total 
focus areas but were based on smaller observed and expected numbers. Lung cancer for the 
total population in the prime area near the Welsbach/General Gas Mantle sites remained 
significantly higher than expected. No cases of thyroid cancer occurred in the prime areas of 
the Montclair/West Orange site.
The results of this analysis indicate that there were no consistent results across the three 
focus areas and relatively few significantly elevated cancer types. It is important to note that
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although each of the focus areas had evidence of complex mixtures of radiologic isotopes (both 
uranium-238 and thorium-232 decay series), the relative amount of contaminants from each 
decay series differed at each of the sites due to the industrial processing of monazite sands 
(thorium-232) vs. camotite ore (radium-226). However, each of the sites was known to 
present health risks from exposure to external sources of gamma radiation in soils and 
structural materials and to the inhalation of emitters of alpha radiation in contaminated air or 
suspended particles of contaminated dust.
All ionizing radiation can cause damage to organic molecules, especially DNA, and 
can, therefore, produce both mutagenic and carcinogenic effects. The probability of 
developing an adverse health effect, such as cancer, is a function of length, route, and 
magnitude of exposure. Although the magnitude of the potential exposure at each of the sites 
was generally relatively low, but above background, the potential length of exposure was long 
and completed exposure pathways were available to residents in each of the areas. However, 
there is little published data available to suggest which types of cancer may be impacted from 
low level exposure to radium-226 or thorium-232.
The main source of information on the health effects of radium deposited in human 
tissues are the U.S. cases of occupational exposure (mostly in radium chemists and dial 
painters, including U.S. Radium employees) and therapeutic exposure during treatment of 
spondylitis and tuberculosis (BEIRIV, 1988; BEIR V, 1990; ATSDR, 1990a). Malignant 
effects have been found for bone sarcomas (especially osteogenic sarcomas) and carcinomas of 
the perinasal sinuses and mastoid air cells. Increased risk of lung cancer has been observed 
among underground miners and quantitatively related to the inhalation of radon daughter 
products (Blot and Fraumeni, 1996). Radon-222 and radon-220 are daughter products of 
uranium-238 and thorium-232, the main contaminants at these sites. In the most definitive 
accumulation of scientific data gathered since 1988, the National Academy of Sciences (NAS) 
in its Health Effects of Exposure to Radon report (BEIR VI, 1999) noted that the data from 
radon studies in homes is consistent with studies of radon health effects in mines. NAS also 
concluded that no evidence exits that shows a threshold of exposure below which radon levels 
are harmless. Weak evidence exists for the induction of leukemia, although at doses far 
greater than those found occupationally or medically.
Studies of thorium workers have shown that breathing thorium dust may increase the 
risk of lung cancer (ATSDR 1997b). Follow-up of patients exposed to thorium dioxide during 
diagnostic radiology showed increased rates of liver cancers, bone sarcomas, and 
myeloproliferative diseases, including leukemia (BEIR IV, 1988; BEIR V, 1990).
Carcinogenic effects of radiation on the bone marrow, breast, thyroid, lung, stomach, 
colon, ovary, and other organs have been reported for atomic bomb survivors and are similar 
to findings reported for other irradiated human populations (BEIR V, 1990). With few
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exceptions, however, the effects have been observed only at relatively high doses. Studies of 
populations chronically exposed to low-level radiation have not shown consistent or conclusive 
evidence of an associated increase in the risk of cancer.
Thyroid cancer was the first of the solid tumors noted to occur at increased frequency 
in atomic bomb survivors (BIER V, 1990). Increased thyroid cancer risk has also been 
reported among persons exposed to therapeutic x-rays and Marshall Islanders exposed to 
radioactive fallout. Females appear to be two to three times more susceptible than males to 
radiogenic and spontaneous thyroid cancer (Ron, 1996).
Since the exposure potential at each of the sites was to relatively low levels and differed 
by radiological isotope, consistent SIR findings across sites may not necessarily be expected.
In any event, due to inherent limitations in this type of investigation, interpretations of these 
data should be done with caution.
A serious limitation of cancer studies of this type is the inability to assess past exposure 
levels in the population. The critical piece of information required to assure a meaningful 
evaluation of these data is actual personal exposure to the contamination over time; that is, 
who was exposed and who was not exposed and the magnitude of the exposure that did occur. 
Since personal exposure information does not exist, residential distance from the contaminated 
site was used as a surrogate measure for potential past exposure. This was accomplished by 
grouping the population living in the selected nearby census blocks into a potentially exposed 
study area. Although distance from the site may have been the best way to estimate past 
potential exposures at the time the study was designed, it is also unlikely that all of the 
residents in these areas were exposed to the contamination. Additionally, the length of 
residence of each case is unknown, thereby potentially adding to exposure misclassification.
The consequence of exposure misclassification would be to bias the results toward the null 
hypothesis of no effect.
Another interpretation problem is that cancer is a chronic disease that takes many years 
after exposure to manifest as clinical disease. The information supplied by the Cancer 
Registry provides only an address at time of diagnosis for each case subject. No information 
is available on length of time an individual may have lived at the address before diagnosis. It 
is possible that some case subjects are new, short-term residents with little or no exposure to 
the sites. Furthermore, former residents who have moved out of the study area just prior to 
diagnosis are not available for analysis. Population mobility cannot be accounted for in this 
study. The current study assumes that in- and out- migration of individuals with cancer will 
offset each other.
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The approach utilized in this study was "census" based, i.e., the entire population of 
the study areas and the State of New Jersey were reviewed in order to calculate sex- and age- 
standardized incidence ratios (SIRs). This census approach (ecologic design) is a practical 
surveillance, or screening, method for cancer incidence. However, information on important 
individual risk factors, such as occupational exposures or personal lifestyle habits (e.g., 
smoking history) were not available for this evaluation. Therefore, these potential risk factors 
cannot be accounted for in this study design and could vary widely within the study area.
Although high-dose radiation has been identified as a risk factor for lung cancer, 
cigarette smoking remains the major known risk factor for this disease (NCI, 1996). 
Epidemiological studies of working populations have also identified asbestos, radon, 
chromium, inorganic arsenic, and chloromethyl ethers as contributing agents to the incidence 
of lung cancer. Little is known about the causes of pancreatic cancer, however, cigarette 
smoking has been the only established risk factor, with a twofold risk for smokers relative to 
nonsmokers (NCI, 1996).
CONCLUSIONS
In conclusion, total cancer incidence and all eleven specific cancer groupings for the 
entire study area were not significantly higher than expected when compared to average State 
incidence rates. Little consistency in the results was detected across focus areas and none of 
the Montclair/West Orange thyroid cases lived in the prime areas closest to the contamination.
Lung cancer incidence in the total study area and two of the focus areas was not higher 
than expected. However, lung cancer incidence was significantly higher than expected in the 
total population living near the Welsbach/General Gas Mantle sites. This higher rate appears 
to be driven by the elevated incidence in males at this focus area. When the prime study areas 
were evaluated, lung cancer incidence in the total population near Welsbach/General Gas 
Mantle remained significantly higher than expected. Lung cancer was not elevated in any of 
the other prime areas.
Pancreatic cancer incidence in the total study area and two of the focus areas was not 
higher than expected. Pancreatic cancer incidence was higher than expected in the total 
population living near the Montclair/West Orange sites. Thyroid cancer in females was higher 
than expected for the Montclair/West Orange sites. When the prime study areas were 
evaluated, neither pancreatic cancer nor thyroid cancer remained higher than expected in any 
of the prime areas.
Since there was little agreement in the results across the focus or prime study areas, it 
is not likely that the few elevations detected are related to site contamination. Consequently, 
no further follow-up of cancer incidence appears warranted at this time.
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Table la . Characteristics of cancer (malignancies) incidence, by year of diagnosis, age
group, race, and sex. Total study area, 1979-1991.
Male Female Total
Diagnosis Year:
1979 26 39 65
1980 32 :40 72
1981 40 33 73
1982 36 36 72
1983 44 43 87
1984 37 39 76
1985 40 41 81
1986 35 42 77
1987 38 33 71
1988 45 32 77
1989 26 30 56
1990 41 28 69
1991 31 33 64
Total 471 469 940
Age Group:
0-9 0 1 1
10-19 3 2 5
20-34 9 27 ; 36
35-49 31 56 I 87
50-64 140 137 i 277
65-79 209 178 387














Table lb . Characteristics of cancer (malignancies) incidence, by year of diagnosis, age
group, race, and sex. U.S. Radium focus area, 1979-1991.
M ale Fem ale Total
Diagnosis Year:
1979 1 5 6
1980 2 1 0 1 2
1981 5 5 1 0
1982 5 5 1 0
1983 6 9 15
1984 1 0 9 19
1985 6 4 1 0
1986 5 8 13
1987 6 5 11
1988 7 5 1 2
1989 5 6 11
1990 5 5 1 0
1991 9 5 14
Total 72 81 153
Age G roup:
0-9 0 1 1
10-19 1 1 2
20-34 1 11 1 2
35-49 4 18 2 2
50-64 19 19 38
65-79 32 23 55
80+ 15 8 23
Race:
W hite 











Table lc. Characteristics of cancer (malignancies) incidence, by year of diagnosis, age
group, race, and sex. Montclair/W. Orange focus area, 1979-1991.
Male Female Total
Diagnosis Year:
1979 15 9 24
1980 4 13 17
1981 16 18 34
1982 16 15 31
1983 17 2 0 37
1984 18 14 32
1985 15 16 31
1986 16 17 33
1987 1 2 11 23
1988 2 2 13 35
1989 13 7 2 0
1990 19 1 0 29
1991 9 13 2 2
Total 192 176 368
Age Group:
0-9 0 0 0
10-19 1 0 1
20-34 4 4 8
35-49 11 17 28
50-64 55 61 116
65-79 84 67 151














Table Id. Characteristics of cancer (malignancies) incidence, by year of diagnosis, age
group, race, and sex. Welsbach/General Gas Mantle focus area, 1979-1991.
Male Female Total
Diagnosis Year:
1979 1 0 25 35
1980 26 17 43
1981 19 1 0 29
1982 15 16 31
1983 2 1 14 35
1984 9 16 25
1985 19 2 1 40
1986 14 17 31
1987 2 0 17 37
1988 16 14 30
1989 8 17 25
1990 17 13 30
1991 13 15 28
Total 207 2 1 2 419
Age Group:
0-9 0 0 0
10-19 1 1 2
20-34 4 1 2 16
35-49 16 2 1 37
50-64 6 6 57 123
65-79 93 8 8 181














Table 2a. Cancer (malignancies) incidence, by type. Total study area, 1979-1991.
Cancer Type Male Female Total
Bladder 30 5 35
Bone and Joint 3 0 3
Brain/Central Nervous System 6 2 8
Breast 4 142 146
Cervix - 19 19
Colorectal 65 81 146
Corpus uteri - 34 34
Esophagus 7 2 9
Eye 0 1 1
Gallbladder 1 5 6
Hodgkin’s Disease 2 3 5
Kidney 1 0 9 19
Larynx 17 3 2 0
Leukemia 14 4 18
Liver 3 4 7
Lung/Pleura 107 43 150
Myeloma 3 5 8
Oral/Pharynx 2 2 7 29
Other Digestive 1 0 1
Other Respiratory 2 2 4
Other Female Genital - 2 2
Other Male Genital 1 - 1
Ovary - 2 2 2 2
Non-Hodgkin’s Lymphoma 16 9 25
Pancreas 17 1 2 29
Prostate 83 - 83
Skin 15 14 29
Small Intestine 0 2 2
Soft Tissue 5 3 8
Stomach 1 2 6 18
Testis 6 - 6
Thyroid 2 11 13
Other or Unknown Primary 17 17 34
Total 471 469 940
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Table 2b. Cancer (malignancies) incidence, by type. U.S. Radium focus area, 1979-1991.
Cancer Type Male Female Total
Bladder 4 2 6
Bone and Joint 2 0 2
Brain/Central Nervous System 1 0 1
Breast 0 28 28
Cervix - 7 7
Colorectal 11 1 0 2 1
Corpus uteri - 5 5
Esophagus 3 0 3
Eye 0 0 0
Gallbladder 0 2 2
Hodgkin’s Disease 0 2 2
Kidney 0 0 0
Larynx 3 1 4
Leukemia 2 2 4
Liver 0 0 0
Lung/Pleura 2 2 3 25
Myeloma 1 1 2
Oral/Pharynx 2 0 2
Other Digestive 0 0 0
Other Respiratory 0 0 0
Other Female Genital - 1 1
Other Male Genital 0 - 0
Ovary - 3 3
Non-Hodgkin’s Lymphoma 1 0 1
Pancreas 2 2 4
Prostate 1 2 - 1 2
Skin 1 3 4
Small Intestine 0 1 1
Soft Tissue 0 3 3
Stomach 0 2 2
Testis 0 - 0
Thyroid 1 2 3
Other or Unknown Primary 4 1 5
Total 72 81 153
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Table 2c. Cancer (malignancies) incidence, by type. Montclair/W. Orange focus area,
1979-1991.
Cancer Type Male Female Total
Bladder 13 0 13
Bone and Joint 1 0 1
Brain/Central Nervous System 3 1 4
Breast 1 55 56
Cervix - 5 5
Colorectal 26 32 58
Corpus uteri - 13 13
Esophagus 1 1 2
Eye 0 1 1
Gallbladder 0 1 1
Hodgkin’s Disease 1 1 2
Kidney 8 4 1 2
Larynx 3 0 3
Leukemia 5 1 6
Liver 2 2 4
Lung/pleura 29 14 43
Myeloma 0 1 1
Oral/Pharynx 1 0 2 1 2
Other Digestive 1 0 1
Other Respiratory 0 0 0
Other Female Genital - 1 1
Other Male Genital 1 - 1
Ovary - 11 11
Non-Hodgkin’s Lymphoma 11 4 15
Pancreas 8 9 17
Prostate 46 - 46
Skin 8 3 11
Small Intestine 0 0 0
Soft Tissue 2 0 2
Stomach 4 1 5
Testis 3 - 3
Thyroid 1 7 8
Other or Unknown Primary 4 6 1 0
Total 192 176 368
25
Table 2d. Cancer (malignancies) incidence, by type. Welsbach/General Gas Mantle focus
area, 1979-1991.
Cancer Type Male Female Total
Bladder 13 3 16
Bone and Joint 0 0 0
Brain/Central Nervous System 2 1 3
Breast 3 59 62
Cervix - 7 7
Colorectal 28 39 67
Corpus uteri - 16 16
Esophagus 3 1 4
Eye 0 0 0
Gallbladder 1 2 3
Hodgkin’s Disease 1 0 1
Kidney 2 5 7
Larynx 11 2 13
Leukemia 7 1 8
Liver 1 2 3
Lung/pleura 56 26 82
Myeloma 2 3 5
Oral/Pharynx 1 0 5 15
Other Digestive 0 0 0
Other Respiratory 2 2 4
Other Female Genital - 0 0
Other Male Genital 0 - 0
Ovary - 8 8
Non-Hodgkin’s Lymphoma 4 5 9
Pancreas 7 1 8
Prostate 25 - 25
Skin 6 8 14
Small Intestine 0 1 1
Soft Tissue 3 0 3
Stomach 8 3 11
Testis 3 - 3
Thyroid 0 2 2
Other or Unknown Primary 9 1 0 19
Total 207 2 1 2 419
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Table 3a. Comparison of the observed and expected cancer (malignancies) incidence.
Total study area, 1979-1991.*
Cancer Type Sex Observed Expected SIR 95% Cl
All Cancers Total 940 935.4 1 . 0 0 0.94 - 1.07
Male 471 442.5 1.06 0 .9 7 -  1.17
Female 469 490.3 0.96 0 .8 7 -  1.05
Bladder Total 35 48.9 0.72 0.50 - 1.00
Male 30 34.8 0 . 8 6 0.58 - 1.23
Female 5 13.2 0.38 * 0 .1 2 -0 .8 9
Bone and Joint Total 3 1.9 1.56 0.31 -4 .5 7
Male 3 1 . 0 3.16 0.64 - 9.24
Female 0 1 . 0 - -
Brain/CNSt Total 8 13.6 0.59 0.25 - 1.16
Male 6 7.3 0.82 0.30 - 1.79
Female 2 6.3 0.32 0.04 - 1.15
Breast Female 142 148.8 0.95 0.80 - 1 . 1 2
Kidney Total 19 22.4 0.85 0.51 - 1.32
Male 1 0 13.1 0.77 0.37 - 1.41
Female 9 9.1 0.99 0.45 - 1.87
Leukemia Total 18 23.0 0.78 0.46 - 1.24
Male 14 12.3 1.14 0 .6 2 -  1.91
Female 4 10.5 0.38 * 0 .1 0 -0 .9 8
Liver Total 7 5.6 1.24 0.50 - 2.56
Male 3 3.6 0.84 0 .1 7 -2 .4 5
Female 4 2 . 0 2.03 0.55 - 5.20
Lung/Pleura Total 150 146.9 1 . 0 2 0 . 8 6  - 1 . 2 0
Male 107 89.8 1.19 0.98 - 1.44
Female 43 55.3 0.78 0.56 - 1.05
NHL§ Total 25 31.4 0.80 0.51 - 1.18
Male 16 15.9 1 . 0 1 0.58 - 1.64
Female 9 15.4 0.58 0 .2 7 -1 .1 1
Pancreas Total 29 24.4 1.19 0.80 - 1.71
Male 17 11.3 1,50 0 .8 8 -2 .4 1
Female 1 2 13.0 0.92 0.48 - 1.61
Thyroid Total 13 9.7 1.35 0.72 - 2.30
Male 2 2.5 0.81 0.09 - 2.93
Female 11 7.3 1.51 0.75 - 2.71
* (Statistically significant (p<  0.05): * =  low),
t  CNS=central nervous system.
§ NHL= non-Hodgkin’s lymphoma.
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Table 3b. Comparison of the observed and expected cancer (malignancies) incidence.
U.S. Radium focus area, 1979-1991.*
Cancer Type Sex Observed Expected SIR 95% Cl
All Cancers Total 153 196.6 0.78 * 0.66-0.91
Male 72 96.9 0.74 * 0.58 - 0.94
Female 81 101.7 0.80 * 0.63 - 0.99
Bladder Total 6 9.7 0.62 0.23 - 1.34
Male 4 7.4 0.54 0.14 - 1.38
Female 2 2.5 0.81 0.09 - 2.92
Bone and Joint Total 2 0.5 4.13 0.46-14.91
Male 2 0.2 8.33 0.94 -30.08
Female 0 0.3 - -
Brain/CNSf Total 1 3.3 0.31 0.00 - 1.71
Male 1 1.8 0.56 0.01 - 3.10
Female 0 1.4 - -
Breast Female 28 32.3 0.87 0.58 - 1.25
Kidney Total 0 4.8 - -
Male 0 2.9 - -
Female 0 1.9 - -
Leukemia Total 4 5.0 0.80 0.22 - 2.06
Male 2 2.8 0.70 0.08 - 2.54
Female 2 2.1 0.94 0.11 - 3.39
Liver Total 0 1.2 _ _
Male 0 0.8 - -
Female 0 0.4 - -
Lung/Pleura Total 25 30.3 0.82 0.53 - 1.22
Male 22 19.6 1.12 0.70 - 1.70
Female 3 11.1 0.27 * 0.05 - 0.79
NHL§ Total 1 6.9 0.15 * 0.00-0.81
Male 1 3.7 0.27 0.00 - 1.49
Female 0 3.1 - -
Pancreas Total 4 4.8 0.83 0.22- 2.12
Male 2 2.5 0.82 0.09 - 2.95
Female 2 2.4 0.83 0.09-3.01
Thyroid Total 3 2.5 1.35 0.09 - 2.90
Male 1 0.6 1.61 0.02 - 8.94
Female 2 1.9 1.04 0.12-3.76
* (Statistically significant (p <  0.05): * =  low),
t  CN S=central nervous system.
§ N H L= non-Hodgkin’s lymphoma.
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Table 3c. Comparison of the observed and expected cancer (malignancies) incidence.
Montclair/W. Orange focus area, 1979-1991.*
Cancer Type Sex Observed Expected SIR 95% Cl
All Cancers Total 368 362.2 1.02 0.91 - 1.13
Male 192 170.7 1.12 0.97 - 1.30
Female 176 189.9 0.93 0.79 - 1.07
Bladder Total 13 19.2 0.68 0.36- 1.16
Male 13 13.6 0.96 0.51 - 1.64
Female 0 5.2 - -
Bone and Joint Total 1 0.7 1.54 0.02 - 8.54
Male 1 0.3 3.11 0.04 -17.32
Female 0 0.3 - -
Brain/CNSt Total 4 5.0 0.81 0.22 - 2.07
Male 3 2.6 1.14 0.23 - 3.34
Female 1 2.3 0.43 0.01 -2.41
Breast Female 55 57.3 0.96 0.72 - 1.25
Kidney Total 12 8.7 1.38 0.71 - 2.42
Male 8 5.0 1.60 0.69 - 3.14
Female 4 3.5 1.13 0.30 - 2.89
Leukemia Total 6 8.6 0.70 0.25 - 1.52
Male 5 4.6 1.10 0.35 - 2.56
Female 1 4.0 0.25 0.00- 1.40
Liver Total 4 2.2 1.82 0.49 - 4.67
Male 2 1.4 1.45 0.16-5.23
Female 2 0.8 2.59 0.29 - 9.35
Lung/Pleura Total 43 57.6 0.75 0.54 - 1.01
Male 29 34.9 0.83 0.56 - 1.19
Female 14 21.8 0.64 0.35 - 1.08
NHL§ Total 15 11.9 1.26 0.70 - 2.07
Male 11 5.9 1.86 0.93 - 3.32
Female 4 6.0 0.67 0.18 - 1.72
Pancreas Total 17 9.6 1 77 ** 1.03-2.83
Male 8 4.4 1.82 0.78-3.58
Female 9 5.2 1.74 0.79 - 3.31
Thyroid Total 8 3.5 2.31 ** 1.01 -4.56
Male 1 0.9 1.11 0.01 -6.17
Female 7 2.6 2.72 ** 1.09-5.61
*( Statistically significant (p< 0.05): ** = high),
t  CNS=central nervous system.
§ NHL= non-Hodgkin’s lymphoma.
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Table 3d. Comparison of the observed and expected cancer (malignancies) incidence.
Welsbach/General Gas Mantle focus area, 1979-1991.*
Cancer Type Sex Observed Expected SIR 95% Cl
All Cancers Total 419 376.7 1.11 ** 1.01 - 1.22
Male 207 174.9 1.18 ** 1.03 - 1.36
Female 212 198.6 1.07 0.93 - 1.22
Bladder Total 16 20.2 0.80 0.46 - 1.30
Male 13 13.8 0.94 0.50 - 1.61
Female 3 5.5 0.55 0.11 - 1.60
Bone and Joint Total 0 0.8 _ _
Male 0 0.4 - -
Female 0 0.4 -
Brain/CNSt Total 3 5.4 0.55 0.11 - 1.61
Male 2 2.9 0.70 0.08-2.51
Female 1 2.5 0.39 0.01 - 2.20
Breast Female 59 59.1 1.00 0.76 - 1.29
Kidney Total 7 9.0 0.78 0.31 - 1.61
Male 2 5.1 0.39 0.04 - 1.42
Female 5 3.7 1.35 0.43-3.14
Leukemia Total 8 9.4 0.85 0.37 - 1.68
Male 7 4.9 1.43 0.57 - 2.94
Female 1 4.4 0.23 0.00 - 1.27
Liver Total 3 2.3 1.32 0.26 - 3.85
Male 1 1.4 0.71 0.01 - 3.96
Female 2 0.8 2.44 0.27 - 8.81
Lung/Pleura Total 82 59.0 1.39 ** 1.11 - 1.73
Male 56 35.2 1.59 ** 1.20-2.06
Female 26 22.5 1.16 0.76 - 1.70
NHL§ Total 9 12.6 0.72 0.33 - 1.36
Male 4 6.2 0.64 0.17 - 1.65
Female 5 6.3 0.79 0.26- 1.85
Pancreas Total 8 10.0 0.80 0.35 - 1.58
Male 7 4.5 1.57 0.63 - 3.24
Female 1 5.4 0.18 0.00- 1.02
Thyroid Total 2 3.7 0.54 0.06- 1.95
Male 0 0.9 - -
Female 2 2.8 0.72 0.08 - 2.60
* (Statistically significant (p<  0.05): * =  low, ** = high),
t  CNS=central nervous system.
§ NHL = non-Hodgkin’s lymphoma.
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Table 4. Childhood cancer (malignancies) incidence, by type. Total study area 1979-1991.
Cancer Type Male Female Total
Bone and Joint 1 0 1
Leukemia 1 0 1
Lung/Pleura 1 0 1
Oral/Pharynx 0 1 1
Ovary - 1 1
Soft Tissue 0 1 1
Total 3 3 6
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Table 5a. Characteristics of cancer (malignancies) incidence, by year of diagnosis, age
group, race, and sex. Total prime area, 1979-1991.
Male Female Total
Diagnosis Year:
1979 6 17 23
1980 11 13 24
1981 14 9 23
1982 18 17 35
1983 16 12 28
1984 11 12 23
1985 21 24 45
1986 11 19 30
1987 17 13 30
1988 15 11 26
1989 7 11 18
1990 13 13 26
1991 7 9 16
Total 167 180 347
Age Group:
0-9 0 0 0
10-19 1 2 3
20-34 3 13 16
35-49 13 19 32
50-64 56 52 108
65-79 70 68 138














Table 5b. Characteristics of cancer (malignancies) incidence, by year of diagnosis, age
group, race, and sex. U.S. Radium prime area, 1979-1991.
Male Female Total
Diagnosis Year:
1979 0 2 2
1980 1 4 5
1981 2 1 3
1982 2 3 5
1983 2 3 5
1984 7 1 8
1985 2 3 5
1986 2 6 8
1987 3 1 4
1988 5 1 6
1989 2 2 4
1990 2 2 4
1991 2 1 3
Total 32 30 62
Age Group:
0-9 0 0 0
10-19 0 1 1
20-34 1 6 7
35-49 1 4 5
50-64 9 7 16
65-79 14 10 24












Table 5c. Characteristics of cancer (malignancies) incidence, by year of diagnosis, age
group, race, and sex. Montclair/W. Orange prime area, 1979-1991.
Male Female Total
Diagnosis Year:
1979 3 1 4
1980 0 2 2
1981 3 5 8
1982 5 4 9
1983 3 3 6
1984 4 2 6
1985 6 7 13
1986 3 4 7
1987 3 2 5
1988 4 3 7
1989 1 0 1
1990 3 3 6
1991 1 2 3
Total 39 38 77
Age Group:
0-9 0 0 0
10-19 1 0 1
20-34 0 0 0
35-49 3 5 8
50-64 10 16 26
65-79 21 9 30














Table 5d. Characteristics of cancer (malignancies) incidence, by year of diagnosis, age
group, race, and sex. Welsbach/General Gas Mantle prime area, 1979-1991.
Male Female Total
Diagnosis Year:
1979 3 14 17
1980 10 7 17
1981 9 3 12
1982 11 10 21
1983 11 6 17
1984 0 9 9
1985 13 14 27
1986 6 9 15
1987 11 10 21
1988 6 7 13
1989 4 9 13
1990 8 8 16
1991 4 6 10
Total 96 112 208
Age Group:
0-9 0 0 0
10-19 0 1 1
20-34 2 7 9
35-49 9 10 19
50-64 37 29 66
65-79 35 49 84












Table 6a. Cancer (malignancies) incidence, by type. Total prime area, 1979-1991.
Cancer Type Male Female Total
Bladder 9 1 10
Bone and Joint 2 0 2
Brain/Central Nervous System 3 2 5
Breast 0 51 51
Cervix - 7 7
Colorectal 23 30 53
Corpus uteri - 13 13
Esophagus 2 2 4
Eye 0 0 0
Gallbladder 0 3 3
Hodgkin’s Disease 1 1 2
Kidney 3 4 7
Larynx 4 1 5
Leukemia 5 1 6
Liver 1 2 3
Lung/Pleura 39 22 61
Myeloma 2 2 4
Oral/Pharynx 8 4 12
Other Digestive 0 0 0
Other Respiratory 2 0 2
Other Female Genital - 2 2
Other Male Genital 0 - 0
Ovary - 8 8
Non-Hodgkin’s Lymphoma 5 4 9
Pancreas 7 3 10
Prostate 30 - 30
Skin 6 6 12
Small Intestine 0 1 1
Soft Tissue 1 0 1
Stomach 5 4 9
Testis 2 - 2
Thyroid 0 2 2
Other or Unknown Primary 7 4 11
Total 167 180 347
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Table 6b. Cancer (malignancies) incidence, by type. U.S. Radium prime area, 1979-1991.
Cancer Type Male Female Total
Bladder 3 1 4
Bone and Joint 1 0 1
Brain/Central Nervous System 1 ' 0 1
Breast 0 12 12
Cervix - 2 2
Colorectal 7 4 11
Corpus uteri - 1 1
Endocrine 0 1 1
Esophagus 1 0 1
Eye 0 0 0
Gallbladder 0 2 2
Hodgkin’s Disease 0 1 1
Kidney 0 0 0
Larynx 0 0 0
Leukemia 1 0 1
Liver 0 0 0
Lung/Pleura 7 0 7
Myeloma 1 0 1
Oral/Pharynx 1 0 1
Other Digestive 0 0 0
Other Respiratory 0 0 0
Other Female Genital - 1 1
Other Male Genital 0 - 0
Ovary - 1 1
Non-Hodgkin’s Lymphoma 0 0 0
Pancreas 2 1 3
Prostate 5 - 5
Skin 1 0 1
Small Intestine 0 1 1
Soft Tissue 0 0 0
Stomach 0 1 1
Testis 0 - 0
Thyroid 0 1 1
Other or Unknown Primary 1 1 2
Total 32 30 62
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Table 6c. Cancer (malignancies) incidence, by type. Montclair/W. Orange prime area,
1979-1991.
Cancer Type Male Female Total
Bladder 1 0 1
Bone and Joint 1 0 1
Brain/Central Nervous System 1 1 2
Breast 0 10 10
Cervix - 1 1
Colorectal 4 11 15
Corpus uteri - 1 1
Esophagus 0 1 1
Eye 0 0 0
Gallbladder 0 0 0
Hodgkin’s Disease 0 0 0
Kidney 1 1 2
Larynx 0 0 0
Leukemia 1 0 1
Liver 0 0 0
Lung/Pleura 6 5 11
Myeloma 0 0 0
Oral/Pharynx 2 0 2
Other Digestive 0 0 0
Other Respiratory 0 0 0
Other Female Genital - 1 1
Other Male Genital 0 - 0
Ovary - 3 3
Non-Hodgkin’s Lymphoma 3 1 4
Pancreas 2 1 3
Prostate 13 - 13
Skin 1 1 2
Small Intestine 0 0 0
Soft Tissue 0 0 0
Stomach 1 0 1
Testis 1 - 1
Thyroid 0 0 0
Other or Unknown Primary 1 0 1
Total 39 38 77
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Table 6d. Cancer (malignancies) incidence, by type. Welsbach/General Gas Mantle prime
area, 1979-1991.
Cancer Type Male Female Total
Bladder 5 0 5
Bone and Joint 0 0 0
Brain/Central Nervous System 1 1 2
Breast 0 29 29
Cervix - 4 4
Colorectal 12 15 27
Corpus Uteri - 11 11
Esophagus 1 1 2
Eye 0 0 0
Gallbladder 0 1 1
Hodgkin’s Disease 1 0 1
Kidney 2 3 5
Larynx 4 1 5
Leukemia 3 1 4
Liver 1 2 3
Lung/Pleura 25 17 42
Myeloma 1 2 3
Oral/Pharynx 5 4 9
Other Digestive 0 0 0
Other Respiratory 3 0 3
Other Female Genital - 0 0
Other Male Genital 0 - 0
Ovary - 4 4
Non-Hodgkin’s Lymphoma 2 3 5
Pancreas 3 1 4
Prostate 12 - 12
Skin 4 5 9
Small Intestine 0 0 0
Soft Tissue 1 0 1
Stomach 4 3 7
Testis 1 - 1
Thyroid 0 1 1
Other or Unknown Primary 5 3 8
Total 96 112 208
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Table 7a. Comparison of the observed and expected cancer (malignancies) incidence.
Total prime area, 1979-1991.
Cancer Type Sex Observed Expected SIR 95% Cl
All Cancers Total 347 344.0 1.01 0.91 - 1.12
Male 167 161.2 1.04 0.88 - 1.21
Female 180 180.7 1.00 0.86-1.15
Bladder Total 10 17.9 0.56 0.27-1.03
Male 9 12.6 0.71 0.33 - 1.35
Female 1 4.9 0.21 0.00- 1.15
Bone and Joint Total 2 0.7 2.76 0.31 -9.95
Male 2 0.4 5.47 0.61 -19.74
Female 0 0.4 - -
Brain/CNSt Total 5 5.1 0.98 0.32-2.30
Male 3 2.7 1.09 0.22 - 3.20
Female 2 2.3 0.86 0.10-3.12
Breast Female 51 54.8 0.93 0.69 - 1.22
Kidney Total 7 8.3 0.85 0.34-1.74
Male 3 4.8 0.63 0.13 - 1.83
Female 4 3.4 1.19 0.32 - 3.04
Leukemia Total 6 8.5 0.71 0.26- 1.54
Male 5 4.6 1.10 0.35-2.56
Female 1 3.9 0.26 0.00- 1.44
Liver Total 3 2.1 1.45 0.29 - 4.24
Male 1 1.3 0.76 0.01 -4.25
Female 2 0.7 2.75 0.31 - 9.94
Lung/Pleura Total 61 54.1 1.13 0.86- 1.45
Male 39 32.8 1.19 0.85 - 1.63
Female 22 20.4 1.08 0.67 - 1.63
NHL§ Total 9 11.6 0.78 0.36 - 1.48
Male 5 5.8 0.86 0.28 - 2.00
Female 4 5.7 0.70 0.19 - 1.80
Pancreas Total 10 9.0 1.12 0.53 - 2.05
Male 7 4.1 1.70 0.68 - 3.50
Female 3 4.8 0.63 0.13 - 1.83
Thyroid Total 2 3.6 0.56 0.06 - 2.03
Male 0 0.9 - -
Female 2 2.7 0.75 0.08 - 2.72
t  CNS= central nervous system.
§ NHL= non-Hodgkin’s lymphoma.
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Table 7b. Comparison of the observed and expected cancer (malignancies) incidence.
U.S. Radium prime area, 1979-1991.
Cancer Type Sex Observed Expected SIR 95% Cl
All Cancers Total 62 68.3 0.91 0.70- 1.16
Male 32 31.3 1.02 0.70- 1.44
Female 30 36.5 0.82 0.55 - 1.17
Bladder Total 4 3.3 1.21 0.33 - 3.10
Male 3 2.3 1.29 0.26 - 3.77
Female 1 0.9 1.13 0.01 -6.28
Bone and Joint Total 1 0.2 5.60 0.07 -31.16
Male 1 0.1 11.15 0.15 -62.04
Female 0 0.1 - -
Brain/CNSt Total 1 1.2 0.85 0.01 - 4.72
Male 1 0.7 1.52 0.02 - 8.44
Female 0 0.5 - -
Breast Female 12 11.6 1.03 0.53 - 1.80
Kidney Total 0 1.7 - -
Male 0 1.0 - -
Female 0 0.7 - -
Leukemia Total 1 1.8 0.57 0.01 - 3.19
Male 1 1.0 1.03 0.01 -5.72
Female 0 0.8 - -
Liver Total 0 0.4 _ _
Male 0 0.3 - -
Female 0 0.1 - -
Lung/Pleura Total 7 10.5 0.67 0.27- 1.37
Male 7 6.4 1.10 0.44 - 2.27
Female 0 4.0 - -
NHL§ Total 0 2.4 _ _
Male 0 1.3 - _
Female 0 1.1 - -
Pancreas Total 3 1.7 1.82 0.37-5.33
Male 2 0.8 2.56 0.29 - 9.23
Female 1 0.9 1.17 0.02 - 6.50
Thyroid Total 1 0.9 1.09 0.01 - 6.05
Male 0 0.2 - -
Female 1 0.7 1.45 0.02 - 8.08
t  CNS= central nervous system.
§ NHL= non-Hodgkin’s lymphoma.
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Table 7c. Comparison of the observed and expected cancer (malignancies) incidence .
Montclair/W. Orange prime areas, 1979-1991.
Cancer Type Sex Observed Expected SIR 95% Cl
All Cancers Total 77 86.8 0.89 0.70 - 1.11
Male 39 39.1 1.00 0.71 - 1.36
Female 38 46.7 0.81 0.58 - 1.12
Bladder Total 1 4.6 0.22 0.00- 1.22
Male 1 3.1 0.32 0.00- 1.81
Female 0 1.3 - -
Bone and Joint Total 1 0.2 6.20 0.08 -34.51
Male 1 0.1 12.60 0.16-70.09
Female 0 0.1 - -
Brain/CNSt Total ' 2 1.2 1.65 0.18-5 .94
Male 1 0.6 1.57 0.02 - 8.75
Female 1 0.6 1.76 0.02 - 9.79
Breast Female 10 14.2 0.70 0.34- 1.29
Kidney Total 2 2.1 0.95 0.11 - 3.44
Male 1 1.2 0.85 0.01 - 4.72
Female 1 0.9 1.15 0.01 - 6.37
Leukemia Total 1 2.1 0.49 0.01 - 2.70
Male 1 1.1 0.93 0.01 - 5.20
Female 0 1.0 - -
Liver Total 0 0.5 _ _
Male 0 0.3 - -
Female 0 0.2 - -
Lung/Pleura Total 11 13.9 0.79 0.39 - 1.41
Male 6 8.1 0.74 0.27 - 1.61
Female 5 5.4 0.93 0.30-2.16
NHL§ Total 4 2.9 1.40 0.38 - 3.58
Male 3 1.4 2.17 0.44 - 6.34
Female 1 1.5 0.69 0.01 - 3.82
Pancreas Total 3 2.3 1.31 0.26-3.84
Male 2 1.0 1.97 0.22-7.12
Female 1 1.3 0.80 0.01 - 4.45
Thyroid Total 0 0.8 - -
Male 0 0.2 - -
Female 0 0.6 - -
t  CNS= central nervous system.
§ NHL= non-Hodgkin’s lymphoma.
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Table 7d. Comparison of the observed and expected cancer (malignancies) incidence.
Welsbach/General Gas Mantle prime area, 1979-1991. *
Cancer Type Sex Observed Expected SIR 95% Cl
All Cancers Total 208 188.9 1.10 0.96 - 1.26
Male 96 90.8 1.06 0.86 - 1.29
Female 112 97.5 1.15 0.95 - 1.38
Bladder Total 5 10.1 0.50 0.16 - 1.16
Male 5 7.2 0.69 0.22 - 1.62
Female 0 2.7 - -
Bone and Joint Total 0 0.4 _ _
Male 0 0.2 - -
Female 0 0.2 - -
Brain/CNSf Total 2 2.7 0.74 0.08 - 2.69
Male 1 1.5 0.69 0.01 - 3.85
Female 1 1.2 0.81 0.01 -4.51
Breast Female 29 29.0 1.00 0.67 - 1.44
Kidney Total 5 4.5 1.11 0.36-2.60
Male 2 2.6 0.76 0.09 - 2.75
Female 3 1.8 1.64 0.33 - 4.80
Leukemia Total 4 4.7 0.85 0.23-2.18
Male 3 2.5 1.19 0.24 - 3.48
Female 1 2.2 0.46 0.01 -2.58
Liver Total 3 1.1 2.62 0.53 - 7.67
Male 1 0.7 1.37 0.02 - 7.64
Female 2 0.4 4.95 0.56 -17.87
Lung/Pleura Total 43 29.7 1.45 ** 1.05 - 1.95
Male 26 18.3 1.42 0.93 - 2.08
Female 17 11.1 1.54 0.89 - 2.46
NHL§ Total 5 6.3 0.80 0.26 - 1.86
Male 2 3.2 0.63 0.07 - 2.29
Female 3 3.1 0.97 0.19-2.83
Pancreas Total 4 5.0 0.80 0.21 - 2.04
Male 3 2.3 1.29 0.26 - 3.78
Female 1 2.7 0.37 0.00 - 2.07
Thyroid Total 1 1.8 0.55 0.01 -3.08
Male 0 0.5 - -
Female 1 1.3 0.75 0.01 -4.1
* (Statistically significant (p< 0.05): * = low, ** = high), 
t  CNS= central nervous system.







U.S. RADIUM AND MONCLAIR/ 
GLEN RIDGE/W. ORANGE SITES
De
law
are
 
Riv
er
